Read/Search this Article
Abstract
Endothelin (ET) has been implicated in the pathogenesis of several cardiovascular disorders because of its powerful vasoconstrictor and growth-promoting properties. The ET family consists of three isoforms, ET-1, ET-2 and ET-3. ET-1 appears to be the predominant member of the family generated by vascular endothelial cells. In view of the multiple cardiovascular actions of ET-1, there has been much interest in its contribution to the pathophysiology of hypertension and arteriosclerosis. We have been investigating the roles of ET_A and ET_B receptors in ET-1-related cardiovascular diseases using subtype-selective ET receptor antagonists and ET_B receptor-deficient animals. Our studies have demonstrated that ET-1 overproduction and ET_A-mediated ET-1 actions seem to play a crucial role in the development of several types of hypertensive and post-ischemic diseases. On the other hand, ET-1 biosynthesis and release are regulated at the transcriptional level, and various endogenous substances are known to stimulate ET-1 gene expression by DNA binding of transcription factors. We and others have recently demonstrated that nuclear factor-κB (NF-κB), a transcription factor with a pivotal role in inducing genes involved in immune, inflammatory and stress responses, is responsible for endothelial ET-1 production. In in vivo studies, agents that can inhibit the NF-κB activation improved the development of ET-1 related cardiovascular diseases. Thus, NF-κB inhibition may be a pertinent treatment for ET-1 related diseases.
Journal
- Journal of the Pharmaceutical Society of Japan [List of Volumes]
-
Journal of the Pharmaceutical Society of Japan 127(9), 1319-1329, 2007-09-01 [Table of Contents]
The Pharmaceutical Society of Japan